Search Results - "Ezelarab, Hend A.A."

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
  2. 2

    Recent updates of fluoroquinolones as antibacterial agents by Ezelarab, Hend A. A., Abbas, Samar H., Hassan, Heba A., Abuo‐Rahma, Gamal El‐Din A.

    Published in Archiv der Pharmazie (Weinheim) (01-09-2018)
    “…Fluoroquinolones remain one of the most important kind of antibacterial agents used nowadays. The emergence of more virulent and resistant strains of bacteria…”
    Get full text
    Journal Article
  3. 3

    Inflammatory setting, therapeutic strategies targeting some pro-inflammatory cytokines and pathways in mitigating ischemia/reperfusion-induced hepatic injury: a comprehensive review by Aboelez, Moustafa O., Ezelarab, Hend A. A., Alotaibi, Ghallab, Abouzed, Deiaa E. Elsayed

    “…Ischemia/reperfusion injury (IRI) is a key determining agent in the pathophysiology of clinical organ dysfunction. It is characterized by an aseptic local…”
    Get full text
    Journal Article
  4. 4
  5. 5

    New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization by Ezelarab, Hend A. A., Ali, Taha F. S., Abbas, Samar H., Sayed, Ahmed M., Beshr, Eman A. M., Hassan, Heba A.

    Published in Molecular diversity (01-04-2024)
    “…New 3-substituted oxindole derivatives were designed and synthesized as antiproliferative agents. The antiproliferative activity of compounds 6a–j was…”
    Get full text
    Journal Article
  6. 6

    New 2-oxoindole derivatives as multiple PDGFRα/ß and VEGFR-2 tyrosine kinase inhibitors by Ezelarab, Hend A.A., Abd El-Hafeez, Amer Ali, Ali, Taha F.S., Sayed, Ahmed M., Hassan, Heba A., Beshr, Eman A.M., Abbas, Samar H.

    Published in Bioorganic chemistry (01-04-2024)
    “…[Display omitted] •Two series based 2-oxoindole derivatives. N-aryl acetamides 6a-o having amide linker and its isoster benzyloxy benzylidenes 9a-p were…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9

    Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia by Ezelarab, Hend A. A., Ali, Taha F. S., Abbas, Samar H., Hassan, Heba A., Beshr, Eman A. M.

    Published in BMC chemistry (12-07-2023)
    “…Fms-like tyrosine kinase 3 (FLT3) mutation mechanisms are among the most common genetic abnormalities detected in about 30% of acute myeloid leukemia (AML)…”
    Get full text
    Journal Article